Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background The antibiotic rifaximin is used to treat non-constipated irritable bowel syndrome (IBS). Methane production is associated with constipation and its severity in constipation-predominant IBS (C-IBS). A previous retrospective study suggested that rifaximin and neomycin was superior to neomycin alone in improving symptoms in methane-positive subjects.Aims To determine the effectiveness of neomycin alone or with rifaximin in improving symptoms in methane-positive C-IBS subjects.Methods A double-blind, randomized, placebo-controlled trial was performed from 2010 to 2013 at three tertiary care centers. Subjects aged 18-65 with C-IBS (Rome II criteria) and breath methane (>3 ppm) meeting the inclusion and exclusion criteria were recruited. Subjects completed a baseline symptom questionnaire rating the severity of abdominal and bowel symptoms on a visual analog scale and were randomized to receive neomycin and placebo or neomycin and rifaximin for 14 days. Symptom severity was assessed by weekly questionnaire for 2 weeks of therapy and 4 additional weeks of follow-up.Results Thirty-one subjects (16 neomycin and placebo, 15 neomycin and rifaximin) were included in the intention-to-treat analysis. Constipation severity was significantly lower in the neomycin and rifaximin group (28.6 ± 30.8) compared to neomycin alone (61.2 ± 24.1) (P = 0.0042), with greater improvement in constipation (P = 0.007), straining (P = 0.017) and bloating (P = 0.020), but not abdominal pain. In the neomycin and rifaximin group, subjects with methane <3 ppm after treatment reported significantly lower constipation severity (30.5 ± 21.8) than subjects with persistent methane (67.2 ± 32.1) (P = 0.020).Conclusions Rifaximin plus neomycin is superior to neomycin alone in improving multiple C-IBS symptoms. This effect is predicted by a reduction in breath methane.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whilst most antibiotics are not suitable for treating excessive methane production, a combination of rifaximin and neomycin have been effective in reducing methanogens with concurrent improvement in constipation symptoms [76-78].”
From Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota (2021) · cites this paper as [76]
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440 · cited 2×
“Consecutive patients (18–65 years of age) who fulfilled the Rome II criteria for C-IBS [2] were recruited.”
BackgroundMethodThe burden of selected digestive diseases in the United States
Sandler, R. S., Everhart, J. E., Donowitz, M., Adams, E., Cronin, K., Goodman, C., Gemmen, E., Shah, S., Avdic, A., & Rubin, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.32978 · Cited by 1,512 · cited 1×
“Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder accounting for significant health care and economic costs in gastroenterology [1].”
BackgroundRifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Self-citationPimentel, M., Lin, H. C., Enayati, P., van den Burg, B., Lee, H.-R., Chen, J. H., Park, S., Kong, Y., & Conklin, J. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00574.2004 · Cited by 508 · cited 2×
“More importantly, a cause-and-effect relationship between methane and transit was suggested based on animal studies [12].”
BackgroundSelf-citationSmall intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499 · cited 1×
“Another hypothesis finds that small intestinal bacterial overgrowth (SIBO) contributes to the pathogenesis of IBS based upon breath testing [5], small bowel culture [6, 7], small bowel qPCR [8] and response to antibiotics [9] in non-C-IBS subjects.”
BackgroundTHABANE, M., KOTTACHCHI, D. T., & MARSHALL, J. K. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03399.x · Cited by 466 · cited 1×
“Based on two meta-analyses, IBS develops in approximately 10 % of subjects after acute gastroenteritis [3, 4].”
BackgroundPostinfectious Irritable Bowel Syndrome-A Meta-Analysis
Halvorson, H. A., Schlett, C. D., & Riddle, M. S. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00654.x · Cited by 352
Menees, S. B., Maneerattannaporn, M., Kim, H. M., & Chey, W. D. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.355 · Cited by 283
Attaluri, A., Jackson, M., Valestin, J., & Rao, S. S. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.655 · Cited by 261 · cited 3×
“Breath test studies suggest that methane production is associated with constipation and C-IBS [10, 11].”
BackgroundSelf-citationThe Degree of Breath Methane Production in IBS Correlates With the Severity of Constipation
Chatterjee, S., Park, S., Low, K., Kong, Y., & Pimentel, M. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01072.x · Cited by 232 · cited 3×
“First and foremost, methane appears to be a marker for C-IBS [13].”
BackgroundSelf-citation
Cited by
Rezaie, A., Buresi, M., Lembo, A., Lin, H., McCallum, R., Rao, S., Schmulson, M., Valdovinos, M., Zakko, S., & Pimentel, M. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.46 · Cited by 852
“…the severity of constipation directly correlated with the methane level ( 50 ) and the choice of antibiotics for the treatment of SIBO diff ers between these two groups as the predominant methanogen in the human gut, Methanobrevibacter smithii , is resistant to many antibiotics ( 22,38,54 ).”
BackgroundSelf-citationAntibiotics as deep modulators of gut microbiota: between good and evil
Ianiro, G., Tilg, H., & Gasbarrini, A. (2016) · Gut · doi:10.1136/gutjnl-2016-312297 · Cited by 625
Global burden of irritable bowel syndrome: trends, predictions and risk factors
Black, C. J., & Ford, A. C. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0286-8 · Cited by 610
A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies
Rodiño-Janeiro, B. K., Vicario, M., Alonso-Cotoner, C., Pascua-García, R., & Santos, J. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0673-5 · Cited by 214
Analysis of 1135 gut metagenomes identifies sex-specific resistome profiles
Sinha, T., Vich Vila, A., Garmaeva, S., Jankipersadsing, S. A., Imhann, F., Collij, V., Bonder, M. J., Jiang, X., Gurry, T., Alm, E. J., et al. (2019) · Gut Microbes · doi:10.1080/19490976.2018.1528822 · Cited by 208
“Antibiotic treatment has been associated with both increased risk for IBS2 and therapeutic effects in IBS, both of which are more common in women.7,39 We therefore sought to test the potential relevance of the observed sex-specific resistome differences to (self-reported) IBS.”
BackgroundMethodInfluential
Metadata
- Authors
- Pimentel, M., Chang, C., Chua, K. S., Mirocha, J., DiBaise, J., Rao, S., & Amichai, M.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Mayo Clinic (US)
- Augusta University (US)
- Corresponding author
- Pimentel, Mark
- Venue
- Digestive Diseases and Sciences
- Published
- 2014-05-01
- Volume
- 59
- Issue
- 6
- Pages
- 1278-1285
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2094665977
- Cited by
- 143
- References
- 17
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 14 · 2023: 11 · 2022: 16 · 2021: 9 · 2020: 20 · 2019: 9 · 2018: 8 · 2017: 9 · 2016: 17 · 2015: 7 · 2014: 2
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- irritable bowel syndrome with constipation, rifaximin, neomycin, breath methane, antibiotic therapy, constipation severity, bloating, straining, abdominal pain
- MeSH terms
- Rifaximin, Adult, Anti-Infective Agents, Breath Tests, Constipation, Female, Gastrointestinal Agents, Humans, Male, Methane, Middle Aged, Neomycin, Rifamycins, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome. https://app.cochat.ai/papers/10.1007/s10620-014-3157-8
- The paper
- Pimentel, M., Chang, C., Chua, K. S., Mirocha, J., DiBaise, J., Rao, S., & Amichai, M. (2014). Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-014-3157-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.